

Report about the activities of the Nordic Urothelial Cancer Group of the Scandinavian Urological Association 2013

As has been the practice for more than a decade, the members of the urothelial cancer group have gathered annually, in early March, for the working group meeting at Sigtuna. Members from all four larger countries were present in the latest meeting in March 2013, when the main topics were: 1) Up-date of the earlier Nordic studies including the CIS-study, the bladder sparing study, and the two Nordic trials on neoadjuvant chemotherapy; 2) preliminary results from a FinnBladder 6 study on intravesical instillations; 3) Presentation of ongoing studies of immunoresponse in bladder cancer and APIM peptide influence on mitomycin C response; and 4) Discussion of a prospective collaboration on a new Scandinavian database focusing on outcome and complications following radical cystectomy. This latter subject will be further discussed at the upcoming gathering of the group during the NUF congress in Sandefjord.

The topics listed above illustrate how the group acts as a forum for fruitful discussions and interchange of ideas.

Recently published paper:

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.

Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group. Eur Urol. 2012 Jun;61(6):1229-38

Jørgen Bjerggaard Jensen
Secretary

Per-Uno Malmström
Chairman